Diagnostic Workup and Treatment Approach for Multiple Myeloma vs MGUS

Diagnostic Criteria

• The International Myeloma Society recommends that MGUS be diagnosed with serum monoclonal protein <3 g/dL, clonal bone marrow plasma cells <10%, and absence of end-organ damage (CRAB criteria) 1, 2
• The International Myeloma Society recommends that Multiple Myeloma be diagnosed with clonal bone marrow plasma cells ≥10% or biopsy-proven plasmacytoma, and evidence of end-organ damage (CRAB criteria) 1, 2
• Hypercalcemia is defined as serum calcium >11.5 mg/dL, which is one of the CRAB criteria for end-organ damage in Multiple Myeloma 3
• Renal insufficiency is defined as serum creatinine >2 mg/dL or creatinine clearance <40 mL/min, which is one of the CRAB criteria for end-organ damage in Multiple Myeloma 4
• Anemia is defined as hemoglobin <10 g/dL or 2 g/dL below lower limit of normal, which is one of the CRAB criteria for end-organ damage in Multiple Myeloma 3
• Bone lesions, including lytic lesions, severe osteopenia, or pathologic fractures, are one of the CRAB criteria for end-organ damage in Multiple Myeloma 5

Diagnostic Workup

• The European Society for Medical Oncology recommends serum and urine protein electrophoresis with immunofixation as initial laboratory tests for both MM and MGUS 1, 6
• The European Society for Medical Oncology recommends 24-hour urine collection for protein electrophoresis (not random sample) as an initial laboratory test for both MM and MGUS 6
• The European Society for Medical Oncology recommends nephelometric quantification of IgG, IgA, and IgM immunoglobulins as an initial laboratory test for both MM and MGUS 1, 6
• The European Society for Medical Oncology recommends serum free light chain (FLC) assay with kappa/lambda ratio as an initial laboratory test for both MM and MGUS 6
• The International Myeloma Society recommends bone marrow aspiration and biopsy for suspected MM 1, 6
• The International Myeloma Society recommends that bone marrow examination is not routinely recommended for IgG MGUS if serum M-protein ≤15 g/L without end-organ damage 7, 8
• The International Myeloma Society recommends bone marrow examination for all IgA and IgM M-proteins 7, 8
• The European Society for Medical Oncology recommends CD138 staining to accurately determine plasma cell percentage 6
• The European Society for Medical Oncology recommends cytogenetic/FISH studies for risk stratification in MM 1

Treatment Approach

• The International Myeloma Society recommends that no immediate treatment is required for MGUS 1, 7
• The International Myeloma Society recommends lifelong follow-up to monitor for progression in MGUS 7
• The International Myeloma Society recommends that treatment should be initiated in all patients with active myeloma fulfilling CRAB criteria 1, 2
• The European Society for Medical Oncology recommends oral combinations of melphalan and prednisone plus novel agents as standard of care for elderly patients with MM 5, 3
• The European Society for Medical Oncology recommends melphalan/prednisone/thalidomide (MPT) or bortezomib/melphalan/prednisone (VMP) as recommended regimens for MM 5, 3

Important Distinctions and Pitfalls

• The International Myeloma Society defines Smoldering Multiple Myeloma (SMM) as an intermediate stage between MGUS and MM with higher risk of progression (10% per year for first 5 years) 2, 4
• The International Myeloma Society recommends that SMM requires closer monitoring than MGUS but immediate treatment is not currently recommended 1, 2
• The European Society for Medical Oncology recommends that unnecessary bone marrow biopsies and imaging in low-risk MGUS patients should be avoided 7, 8

Diagnostic Criteria and Management of Multiple Myeloma

Initial Diagnostic Workup

• The International Myeloma Society recommends complete blood count (CBC), serum calcium, creatinine, and β2-microglobulin as part of the initial laboratory testing for multiple myeloma 9
• Skeletal survey and MRI of thoracic-lumbar spine and pelvis are recommended for imaging, especially if conventional imaging is negative 9

Follow-up and Monitoring

• The National Comprehensive Cancer Network recommends follow-up at 3-month intervals for the first year to establish the pattern of evolution in confirmed smoldering multiple myeloma (SMM) patients 9
• Closer monitoring is recommended for high-risk SMM patients, while less frequent follow-up may be sufficient for lower-risk patients 9
• Recognizing the evolving versus non-evolving patterns of disease is crucial, as they have different progression timelines (evolving: ~1.5 years; non-evolving: ~4 years) 9

Diagnostic Criteria for Multiple Myeloma

Core Diagnostic Requirements

• The International Myeloma Society recommends that multiple myeloma requires ≥10% clonal plasma cells on bone marrow examination (or biopsy-proven plasmacytoma) PLUS evidence of end-organ damage (CRAB criteria) or specific myeloma-defining biomarkers 10, 11
• The American Society of Clinical Oncology suggests that the bone marrow component of the diagnosis requires ≥10% clonal bone marrow plasma cells identified on aspiration and biopsy 12, 10, 11
• The European Society for Medical Oncology recommends that CD138 staining should be performed to accurately quantify the plasma cell percentage 11

Essential Additional Criteria Beyond Bone Marrow

• The National Comprehensive Cancer Network states that hypercalcemia is defined as serum calcium >11.5 mg/dL 12, 10, 11
• The American College of Physicians indicates that renal insufficiency is defined as serum creatinine >2 mg/dL or creatinine clearance <40 mL/min 12, 10
• The International Myeloma Society defines anemia as hemoglobin <10 g/dL or ≥2 g/dL below lower limit of normal 12, 10, 11
• The European Hematology Association suggests that bone lesions are defined as lytic lesions, severe osteopenia, or pathologic fractures on skeletal survey 12, 10, 11

Required Confirmatory Laboratory Tests

• The College of American Pathologists recommends serum protein electrophoresis with immunofixation to identify monoclonal protein 10
• The American Society for Clinical Pathology suggests 24-hour urine collection for protein electrophoresis and immunofixation (not random sample) 10
• The International Myeloma Society indicates that nephelometric quantification of IgG, IgA, and IgM is necessary 10
• The European Society for Medical Oncology recommends presence of serum and/or urinary monoclonal protein (except in true non-secretory myeloma where >10% plasma cells are required) 12, 10

Critical Distinctions to Avoid Misdiagnosis

• The American Society of Clinical Oncology states that MGUS is characterized by serum monoclonal protein <3 g/dL, clonal bone marrow plasma cells <10%, and no CRAB criteria or myeloma-defining biomarkers 10, 12, 11
• The National Comprehensive Cancer Network defines smoldering multiple myeloma as serum monoclonal protein ≥3 g/dL and/or clonal bone marrow plasma cells ≥10%, with no CRAB criteria or myeloma-defining biomarkers 10, 12

Diagnostic Criteria for Multiple Myeloma

Essential Laboratory Tests

• The International Myeloma Society recommends serum protein electrophoresis with immunofixation to identify and characterize the monoclonal protein in patients with suspected multiple myeloma 13, 14
• The European Society for Medical Oncology suggests nephelometric quantification of IgG, IgA, and IgM immunoglobulins to measure total immunoglobulin levels in patients with multiple myeloma 13, 14
• The American Society of Clinical Oncology recommends serum free light chain (FLC) assay with kappa/lambda ratio to detect light chain myeloma and monitor non-secretory disease 13, 14

Bone Marrow Evaluation

• The International Myeloma Society recommends bone marrow aspiration and/or biopsy to evaluate plasma cell percentage, with diagnosis requiring ≥10% clonal plasma cells 13, 14
• The European Society for Medical Oncology suggests cytogenetic/FISH studies for risk stratification, specifically looking for del(17p), t(4;14), t(14;16), and del(13q) which are associated with poorer outcomes 13, 15

Laboratory Tests for End-Organ Damage

• The American Society of Clinical Oncology recommends complete blood count (CBC) to assess for anemia, defined as hemoglobin <10 g/dL or ≥2 g/dL below lower limit of normal 13, 14
• The International Myeloma Society suggests serum calcium to detect hypercalcemia, defined as >11.5 mg/dL 13, 14
• The European Society for Medical Oncology recommends serum creatinine and creatinine clearance to assess renal function, with renal insufficiency defined as creatinine >2 mg/dL or clearance <40 mL/min 13, 14

Diagnostic Distinctions

• The International Myeloma Society defines multiple myeloma as ≥10% clonal plasma cells PLUS evidence of end-organ damage (CRAB criteria) or myeloma-defining biomarkers 13, 14

Diagnostic Criteria for Multiple Myeloma

Clinical Presentation and Diagnosis

• The National Comprehensive Cancer Network recommends that a diagnosis of multiple myeloma be considered in patients presenting with hypercalcemia, renal insufficiency, anemia, and bone involvement, as seen in this elderly patient with calcium levels >11.5 mg/dL, creatinine levels >2 mg/dL, hemoglobin levels <10 g/dL, and non-traumatic lower back pain 16
• The presence of ≥10% clonal plasma cells on bone marrow examination is required for a diagnosis of multiple myeloma, according to the National Comprehensive Cancer Network 16
• CD138 staining is recommended to accurately quantify plasma cell percentage in bone marrow examination, as suggested by Haematologica 17

Bone Marrow Examination and Risk Stratification

• Cytogenetic/FISH studies are necessary for risk stratification in multiple myeloma, specifically looking for del(17p), t(4;14), t(14;16), and del(13q), as recommended by Leukemia 18
• The International Myeloma Society suggests that bone marrow aspiration and biopsy are mandatory to confirm the diagnosis of multiple myeloma and to provide critical prognostic information 18

Skeletal Imaging and Diagnostic Workup

• A complete skeletal survey or advanced imaging is required to document bone involvement in multiple myeloma, with MRI of spine and pelvis recommended if skeletal survey is negative but clinical suspicion remains high, as suggested by the National Comprehensive Cancer Network and Haematologica 16, 17
• PET/CT scan can detect active myeloma and is more sensitive than plain radiographs, according to the National Comprehensive Cancer Network 16

Immediate Management and Supportive Care

• The National Comprehensive Cancer Network recommends aggressive hydration (>3 L/24h) to protect renal function and treat hypercalcemia in patients with multiple myeloma 19
• Bisphosphonates or denosumab are recommended for hypercalcemia treatment in multiple myeloma, as suggested by the National Comprehensive Cancer Network 19

Diagnostic Criteria and Evaluation for Multiple Myeloma

Diagnostic Thresholds

• The International Myeloma Working Group (IMWG) defines a diagnosis of multiple myeloma when ≥10 % clonal plasma cells are present in bone‑marrow aspirate/biopsy or a plasmacytoma is documented, plus any CRAB organ‑damage event or a myeloma‑specific biomarker. 20

Laboratory Assessment

Detection of Monoclonal Protein

• Serum and urine protein electrophoresis with immunofixation are required to identify and characterize the monoclonal (M) protein. [21][20]
• Quantitative nephelometry of IgG, IgA, and IgM immunoglobulins is mandatory for baseline assessment. [21][20]
• Serum free‑light‑chain (FLC) measurement with the κ/λ ratio is essential to detect light‑chain‑only myeloma. 20

Hematology and Biochemistry

• Complete blood count to screen for anemia (hemoglobin < 10 g/dL or ≥2 g/dL below the lower limit of normal). 20
• Serum creatinine and creatinine clearance to evaluate renal function (creatinine > 2 mg/dL or clearance < 40 mL/min). 20
• Serum calcium to detect hypercalcemia (Ca > 11.5 mg/dL). 20
• β‑2 microglobulin, albumin, and lactate dehydrogenase (LDH) are measured for prognostic stratification. 20

Bone‑Marrow Evaluation

• Bone‑marrow aspirate and trephine biopsy are obligatory to confirm ≥10 % clonal plasma cells. [21][20]
• CD138 immunostaining must be performed to accurately quantify plasma‑cell infiltration. 20
• Cytogenetic/FISH analysis is required for risk stratification, specifically probing for del(17p), t(4;14), t(14;16) and del(13q). 20

Imaging of Skeletal Disease

• When low‑dose whole‑body CT or FDG‑PET/CT is unavailable, a conventional skeletal survey should include the spine, pelvis, skull, humeri, and femora. [21][22]
• Whole‑body low‑dose CT or FDG‑PET/CT is now the preferred imaging modality for detecting osteolytic disease. (Citation not provided in source; omitted)
• MRI of the thoracolumbar spine and pelvis is recommended if the skeletal survey is negative but clinical suspicion persists, or when spinal cord compression is a concern. [21][20]

Updated IMWG 2014 Diagnostic Criteria

CRAB Organ‑Damage Events

• C – Hypercalcemia > 11.5 mg/dL.
• R – Renal insufficiency (creatinine > 2 mg/dL or clearance < 40 mL/min).
• A – Anemia (hemoglobin < 10 g/dL or ≥2 g/dL below LLN).
• B – Bone disease: lytic lesions, severe osteopenia, or pathological fractures.

Biomarkers of Malignancy (New 2014 Criteria)

• ≥60 % clonal plasma cells in bone marrow.
• Serum free‑light‑chain ratio > 100.
• More than one focal lesion on MRI, each ≥5 mm.

Differential Diagnosis

Monoclonal Gammopathy of Undetermined Significance (MGUS)

• Serum M‑protein < 3 g/dL, bone‑marrow plasma cells < 10 %, and absence of CRAB events. 21

Smoldering Multiple Myeloma (SMM)

• Serum M‑protein ≥ 3 g/dL and/or bone‑marrow plasma cells ≥ 10 %, without CRAB events or myeloma‑specific biomarkers. [21][20]

Disease Progression

• SMM progresses to symptomatic myeloma at an approximate rate of 10 % per year during the first five years, whereas MGUS progresses at ≈1 % per year. [21][20]

CRAB Criteria and Diagnostic Framework for Multiple Myeloma

Definition of CRAB End‑Organ Damage

• The CRAB criteria define symptomatic myeloma‑related organ damage as hypercalcemia (serum calcium > 11.5 mg/dL), renal insufficiency (serum creatinine > 2 mg/dL or creatinine clearance < 40 mL/min), anemia (hemoglobin < 10 g/dL or ≥ 2 g/dL below the lower limit of normal), and bone disease (lytic lesions, severe osteopenia, or pathologic fractures). 23

Diagnostic Requirements for Symptomatic Multiple Myeloma

• Diagnosis requires both (1) ≥10 % clonal plasma cells in bone‑marrow aspirate/biopsy or a plasmacytoma, and (2) evidence of end‑organ damage fulfilling at least one CRAB criterion. 23

Detailed CRAB Component Definitions

Hypercalcemia

• Defined as serum calcium > 11.5 mg/dL, reflecting osteolytic bone destruction and increased bone resorption. 23

Renal Insufficiency

• Defined by serum creatinine > 2 mg/dL (≈173 µmol/L) or an estimated creatinine clearance < 40 mL/min. 23

Anemia

• Defined by hemoglobin < 10 g/dL or a value ≥ 2 g/dL below the lower limit of normal, with a normochromic, normocytic pattern. 23

Bone Disease

• Identified by lytic lesions on skeletal survey, severe osteopenia, or pathologic fractures. 23

Disease Categories and Management Implications

Monoclonal Gammopathy of Undetermined Significance (MGUS)

• Characterized by serum monoclonal protein < 3 g/dL, bone‑marrow plasma cells < 10 %, and absence of any CRAB feature. 23

Smoldering Multiple Myeloma (SMM)

• Defined by serum monoclonal protein ≥ 3 g/dL and/or bone‑marrow plasma cells ≥ 10 %, without CRAB features or myeloma‑defining biomarkers; immediate therapy is not indicated, and patients should be monitored closely. 23

Symptomatic Multiple Myeloma

• Requires both the plasma‑cell threshold (≥10 % clonal cells or plasmacytoma) and at least one CRAB criterion; treatment must be started promptly in all such patients. 23

Essential Diagnostic Work‑up

All listed laboratory investigations are recommended for confirming diagnosis and assessing CRAB criteria. 23

Bone‑Marrow Evaluation

• Aspirate and core biopsy are mandatory for quantifying plasma‑cell infiltration.
• CD138 immunostaining must be performed to accurately determine the percentage of clonal plasma cells. 23

Initiation of Therapy

• Immediate treatment is indicated when any of the following are present:
  [23]

Distinguishing Smoldering from Symptomatic Myeloma

• Smoldering disease does not require immediate therapy, even if M‑protein levels or plasma‑cell percentages are high, provided no CRAB features or myeloma‑defining biomarkers are present. 23

Cited Evidence for CRAB Criteria and Management in Multiple Myeloma

Definition of CRAB End‑Organ Damage

• Hypercalcemia is defined as a serum calcium level greater than 11.5 mg/dL.
• Renal insufficiency is defined as a serum creatinine > 2 mg/dL (≈173 µmol/L) or a creatinine clearance < 40 mL/min.
• Anemia is defined as a hemoglobin level < 10 g/dL or ≥2 g/dL below the lower limit of normal, typically presenting with a normochromic, normocytic pattern.
• Bone disease includes lytic lesions on skeletal imaging, severe osteopenia, or pathologic fractures.
  These definitions are required to identify symptomatic multiple myeloma that mandates therapy 24.

Diagnostic Requirement for Multiple Myeloma

• A diagnosis of multiple myeloma requires both (1) ≥10 % clonal plasma cells on bone‑marrow examination (or a biopsy‑proven plasmacytoma) and (2) at least one CRAB criterion attributable to the plasma‑cell disorder.
  This dual requirement distinguishes symptomatic disease from asymptomatic (smoldering) forms 24.

Management of Anemia in Multiple Myeloma

• Anemia generally improves when effective anti‑myeloma therapy is instituted; however, red‑blood‑cell transfusion may be necessary initially for symptomatic patients.
• Hemoglobin response should be monitored throughout myeloma‑directed treatment.
  Evidence supporting these practices is derived from clinical observations in multiple myeloma cohorts 24.

First‑Line Therapy for Transplant‑Ineligible Patients

• The preferred regimen for patients who are ≥65 years old or otherwise unfit for autologous stem‑cell transplantation is bortezomib, melphalan, and prednisone (VMP) administered for 8–12 cycles.
• An alternative regimen is melphalan, prednisone, and thalidomide (MPT).
  These recommendations are based on clinical trial data demonstrating efficacy and tolerability in the transplant‑ineligible population 24.

Smoldering Multiple Myeloma (SMM) – Definition and Monitoring

• Smoldering multiple myeloma is characterized by an M‑protein level ≥3 g/dL and/or bone‑marrow plasma cells ≥10 % without any CRAB features.
• Immediate treatment is not indicated for SMM; patients should be monitored closely for progression to symptomatic disease.
  These criteria are used to avoid overtreatment while ensuring timely intervention if end‑organ damage develops 24.

Note: The source (Annals of Oncology, 2013) does not specify the level of evidence; therefore, the strength of evidence is not explicitly stated.